Passa al contenuto
Merck
Tutte le immagini(2)

Documenti fondamentali

Visualizza tutta la documentazione

32236

Supelco

Firocoxib

VETRANAL®, analytical standard

Sinonimo/i:

3-Cyclopropylmethoxy-4-(4-methanesulfonylphenyl)-5,5-dimethyl-5H-furan-2-one

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

10 MG
CHF 226.00

CHF 226.00

Spedizione prevista il01 giugno 2025

Richiedi un ordine bulk
Tutte le immagini(2)

Scegli un formato

Cambia visualizzazione
10 MG
CHF 226.00

About This Item

Formula empirica (notazione di Hill):
C17H20O5S
Numero CAS:
189954-96-9
Peso molecolare:
336.40
Beilstein:
8335837
Numero MDL:
MFCD09837800
Codice UNSPSC:
41116107
ID PubChem:
329754109
NACRES:
NA.24

CHF 226.00

Spedizione prevista il01 giugno 2025

Richiedi un ordine bulk

Grado

analytical standard

Livello qualitativo

100

Nome Commerciale

VETRANAL®

tecniche

HPLC: suitable
gas chromatography (GC): suitable

applicazioni

forensics and toxicology
veterinary

Formato

neat

Stringa SMILE

O=S(C1=CC=C(C2=C(OCC3CC3)C(OC2(C)C)=O)C=C1)(C)=O

InChI

1S/C17H20O5S/c1-17(2)14(12-6-8-13(9-7-12)23(3,19)20)15(16(18)22-17)21-10-11-4-5-11/h6-9,11H,4-5,10H2,1-3H3
FULAPETWGIGNMT-UHFFFAOYSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Prodotti consigliati

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.

Note legali

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
BCCM9523
BCCK3367
BCCF6251
BCBX0038
BCBV7510

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Laura T Letendre et al.
American journal of veterinary research, 69(11), 1399-1405 (2008-11-05)
To determine pharmacokinetic parameters and variables, firocoxib concentrations in urine and plasma, urine-to-plasma ratios, and the urine depletion profile of firocoxib and to evaluate whether the pharmacokinetic behavior of firocoxib was governed by linear processes after multiple doses of firocoxib
A Autefage et al.
The Veterinary record, 168(23), 617-617 (2011-06-07)
Thirty-nine client-owned dogs with osteoarthritis were treated with 5 mg/kg firocoxib administered orally, once a day for 52 weeks. Veterinary examinations were performed on approximately days 0, 15, 90, 180, 270 and 360. Twenty-five dogs completed the study. The withdrawal
William G Ryan et al.
Veterinary therapeutics : research in applied veterinary medicine, 8(4), 263-271 (2008-01-10)
Veterinarians currently have a choice of six registered NSAIDs for use in the management of canine osteoarthritis. There is a need for data to clarify whether there is an increased risk of side effects occurring in the event of a
L Goodman et al.
Journal of veterinary internal medicine, 23(1), 56-62 (2009-01-30)
Little is known about the effect of dual cyclooxygenase (COX) and lipoxygenase inhibition on canine gastric mucosal healing. This study compares the effects of putative dual COX and 5-lipoxygenase inhibition with that of COX-2 selective inhibition on gastric mucosal lesion
W Back et al.
Equine veterinary journal, 41(3), 309-312 (2009-05-28)
Lameness is a highly prevalent condition in horses and the principal cause of removal from athletic activity. In clinical studies to evaluate nonsteroidal anti-inflammatory drug therapies, force plates are commonly used to assess improvement of lameness objectively. To use a
Visualizza tutti i documenti correlati

Questions

Reviews

No rating value

Active Filters

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.